Domača stranALNOV • EPA
add
Novacyt SA
Prejšnji trg. dan.
0,75 €
Dnevni razpon
0,72 € - 0,76 €
Letni razpon
0,45 € - 1,59 €
Tržna kapitalizacija
52,18 mio. EUR
Povprečni obseg
2,09 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
EPA
Borzne novice
CNBC
pred 20 urami
After a week of records, there’s one main market event that could change
everything
0,13 %
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (GBP) | dec. 2023info | Sprememba L/L |
|---|---|---|
Prihodek | 4,12 mio. | 81,82 % |
Stroški poslovanja | 12,52 mio. | 48,31 % |
Čisti dohodek | −9,97 mio. | −17,10 % |
Čista dobičkovnost prihodkov | −242,04 | 35,59 % |
Earnings per share | — | — |
EBITDA | −7,10 mio. | −41,10 % |
Efektivna davčna stopnja | 2,93 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (GBP) | dec. 2023info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 44,06 mio. | −49,34 % |
Skupna sredstva | 133,82 mio. | −5,03 % |
Skupne obveznosti | 46,57 mio. | 81,32 % |
Celoten lastniški kapital | 87,24 mio. | — |
Shares outstanding | 70,63 mio. | — |
Razmerje P/B | 0,60 | — |
Donosnost sredstev | −21,46 % | — |
Donosnost kapitala | −28,44 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (GBP) | dec. 2023info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −9,97 mio. | −17,10 % |
Denar iz dejavnosti | −9,65 mio. | −59,94 % |
Denar iz naložb | −7,47 mio. | −3.853,70 % |
Denar iz financiranja | −1,72 mio. | −1.360,85 % |
Neto sprememba denarnih sredstev | −18,84 mio. | −197,44 % |
Prost denarni tok | −3,81 mio. | −56,02 % |
Vizitka
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Generalni direktor
Datum ustanovitve
2006
Spletno mesto
Zaposleni
237
